Healthcare Services

Rising Lifestyle Disorders Supporting Expansion in Type 2 Diabetes Market

April 28, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Type 2 Diabetes Market Expected To Reach Based On Its 2026 Value?

The type 2 diabetes market size has seen robust growth in recent years. It is projected to expand from $51.47 billion in 2025 to $55.53 billion in 2026, at a compound annual growth rate (CAGR) of 7.9%. The market’s historical growth can be attributed to the escalating global prevalence of obesity, increased sedentary lifestyles, the expansion of oral antidiabetic drug availability, growing screening for metabolic disorders, and improved access to primary diabetes care.

The type 2 diabetes market is anticipated to show significant expansion over the next few years. It will grow to $78.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. This growth during the forecast period is driven by factors such as an increasing demand for therapies focused on weight management, a rising embrace of personalized diabetes treatment approaches, the expansion of digital therapeutic platforms, a growing emphasis on preventive diabetes management, and increased investments in next-generation antidiabetic drugs. Notable trends expected in this period include the increasing adoption of GLP-1 receptor agonists, a heightened focus on cardiometabolic risk management, the growing application of combination drug therapies, the expansion of lifestyle-integrated treatment strategies, and an enhanced emphasis on achieving long-term glycemic control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

Which Drivers Are Supporting The Type 2 Diabetes Market Growth?

The escalating incidence of obesity and heart disease is projected to fuel the growth of the type 2 diabetes market moving forward. Obesity is defined as a medical state where excessive body fat has accumulated to an unhealthy degree, while heart disease refers to various conditions that impact the heart and its blood vessels. Elevated body weight increases the probability of insulin resistance, leading to high blood sugar levels and the subsequent development of type 2 diabetes. Conversely, high blood sugar levels can damage the blood vessels and nerves that regulate the heart and its vessels, contributing to heart disease. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental entity, reported that approximately one in eight people globally were struggling with obesity. This included 2.5 billion adults (aged 18 years and older) who were overweight, with 890 million of them living with obesity. Among adults, 43% were overweight, and 16% were classified as obese. Additionally, the number of overweight children under the age of 5 reached 37 million. Therefore, the rising rates of obesity and heart disease are driving the expansion of the type 2 diabetes market.

Which Segment Classifications Are Used In The Type 2 Diabetes Market Segment Analysis?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin, Buformin, Phenformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

Which Trends Are Expected To Impact The Type 2 Diabetes Market?

Leading companies in the type 2 diabetes market are concentrating on developing advanced solutions, such as extended-indication SGLT2/GLP-1 combination therapies, to achieve improved glycemic control, mitigate comorbidities, and enhance patient adherence. These extended-indication SGLT2/GLP-1 combination therapies are pharmaceutical regimens combining sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (or their fixed-dose combinations) to concurrently address blood glucose regulation, obesity, and cardiovascular and renal outcomes in type 2 diabetes patients. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, obtained U.S. FDA approval for Farxiga (dapagliflozin) for the paediatric type 2 diabetes indication (age 10 years and older), extending its usage beyond adult populations and signifying a strategy for a broader patient base. This particular innovation provides once-daily oral dosing for younger patients, incorporates cardiometabolic and renal protection data, and enables market expansion into paediatric and early-stage type 2 diabetes segments, consequently stimulating growth in the global type 2 diabetes market.

Which Firms Are Contributing To The Type 2 Diabetes Market Ecosystem?

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Get The Full Type 2 Diabetes Market Report:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Where Is The Type 2 Diabetes Market Most Concentrated Geographically?

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Type 2 Diabetes Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Browse Through More Reports Similar to the Global Type 2 Diabetes Market 2026, By The Business Research Company

Type 1 Diabetes Market Report 2026

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Antidiabetics Market Report

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Diabetes Care Devices Market

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795